Market Assessment, Renal Anemia Current Treatment EU5 2016 Report

Renal anemia is a serious and common complication of chronic kidney disease (CKD). An in-depth examination of the drivers and obstacles facing nephrologists provides greater insights on product positioning and marketing within the renal anemia space. How is renal anemia being treated, and what are the factors impacting those treatment decisions? This content stream explores how dialysis and nondialysis CKD patients with renal anemia are diagnosed, treated, and managed within France, Germany, Italy, Spain and the UK.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Renal Anemia | Current Treatment | EU5 | 2016

Related Market Assessment Reports

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis (US)

Migraine – Current Treatment – Detailed, Expanded Analysis (EU5)

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)

Male Hypogonadism – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)